Akums Drugs and Pharmaceuticals, a prominent player in the pharmaceutical sector, is set to make its debut in the stock market with an Initial Public Offering (IPO) worth ₹1,856.74 crores. The IPO comprises a fresh issue of 1 crore shares, valued at ₹680.00 crores, and an offer for sale of 1.73 crore shares, totaling ₹1,176.74 crores.
Investors keen on participating in the Akums Drugs and Pharmaceuticals IPO can do so between July 30, 2024, and August 1, 2024. The allotment process is expected to conclude on Friday, August 2, 2024. Once the allotment is finalized, the company’s shares will be listed on both the Bombay Stock Exchange (BSE) and the National Stock Exchange (NSE), with a tentative listing date set for Tuesday, August 6, 2024.
Akums Drugs & Pharmaceuticals Limited serves as a pharmaceutical product manufacturer, providing an extensive array of offerings such as oral solids, oral liquids, injectables, cosmetics, ayurvedic, and nutraceuticals. Established in 2004, Akums operates as a pharmaceutical Contract Development and Manufacturing Organization (CDMO), delivering integrated solutions for pharmaceutical companies seeking specific development and business goals.
The price band for the Akums Drugs and Pharmaceuticals IPO has been fixed at ₹646 to ₹679 per share. Retail investors can apply for a minimum lot size of 22 shares, requiring an investment of ₹14,938. For non-institutional investors (sNII), the minimum lot size is 14 lots (308 shares), amounting to ₹209,132. Meanwhile, qualified institutional buyers (bNII) can invest in a minimum of 67 lots (1,474 shares), totaling ₹1,000,846.
The book-running lead managers for the Akums Drugs and Pharmaceuticals IPO include ICICI Securities Limited, Axis Bank Limited, Citigroup Global Markets India Private Limited, and Ambit Private Limited. Link Intime India Private Ltd serves as the registrar for this significant market entry.
Akums Drugs and Pharmaceuticals IPO Details:
| Company Name | Akums Drugs and Pharmaceuticals Limited |
| Sector | Pharmaceuticals |
| IPO Type | Mainboard |
| IPO Open date | 30th July 2024 |
| IPO Close date | 01st Aug 2024 |
| OFS | |
| Listing Exchanges | NSE, BSE |
| Share Holding Pre-issue | |
| DRHP Draft Prospectus | Click to check |
| RHP Draft Prospects | Click to check |
Akums Drugs and Pharmaceuticals IPO Lot Size:
| Application | Lot Size | Shares | Amount |
| Retail (Min) | 1 | 22 | 14,938 |
| sHNI (Min) | 14 | 308 | 2,09,132 |
| bHNI (Min) | 67 | 1474 | 10,00,846 |
Akums Drugs and Pharmaceuticals IPO Timeline:
| IPO Open Date | 30th July 2024 |
| IPO Close Date | 01st Aug 2024 |
| Basis of Allotment | 02nd Aug 2024 |
| Refund Initiation Date | 05th Aug 2024 |
| Shares Credit to Demat | 05th Aug 2024 |
| Listing Date | 06th Aug 2024 |
Things to Consider before applying for an IPO
Financial Performance: Review Akums Drugs and Pharmaceuticals’ financials to understand its revenue, profitability, and growth prospects.
Industry Outlook: Consider the overall health of India’s Pharmaceutical Industry.
Valuation: Compare the price band to similar companies in the industry to see if the IPO is priced fairly.
Management Team: Research the experience and capabilities of the management team.
Our Verdict
This IPO offers a good opportunity to invest in Akums Drugs and Pharmaceuticals and be a part of its growth.
FAQ
What is Grey Market Premium (GMP)?
The Grey Market Premium (GMP) represents the price at which an Initial Public Offering (IPO) is traded in the unregulated grey market before its official listing. It serves as an indicator of how the IPO might perform on the listing day. Seeing the latest GMP, investors can estimate the listing performance of the IPO.
